Anzeige
Mehr »
Login
Sonntag, 28.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Nurexone Biologic: Jetzt diese wirklich einzigartige Chance ergreifen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
64 Leser
Artikel bewerten:
(0)

BiO2 Medical's combined triple lumen/IVC Filter marketed as the Angel' Catheter receives CE Mark, and will be introduced at the United Kingdom Intensive Care Society's 'State of the Art' Meeting

SAN ANTONIO, Dec. 9, 2012 /PRNewswire/ --BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, is pleased to announce CE Mark approval for the triple lumen Angel' Catheter. The Angel' Catheter is a Nitinol, Inferior Vena Cava (IVC) filter, permanently attached to a central venous catheter (CVC) for the use of preventing Pulmonary Embolism (PE) in critically ill patients. Placed at the patient's bedside without the need for fluoroscopy, the Angel' Catheter provides instant protection from PE and is the first IVC Filter to receive CE Mark approval for prophylactic indications.

BiO2 Medical will introduce the Angel' Catheter in the United Kingdom, with an exhibition booth at the UK Intensive Care Society's 'State of the Art' Meeting in London, England from December 10-12, 2012. BiO2 Medical is sponsoring a lunch symposium on Tuesday, December 11th, 2012, at the 'State of the Art' meeting entitled, "Improved PE Prevention in the ITU: Angel' Catheter-Bedside IVC Filter Prophylaxis." Chairing the symposium will be Dr. Max Jonas, Consultant Anesthetist and Intensivist at Southampton University Hospital in Southampton, UK. Speaking at the lunch symposium will be Dr. Andy Eynon, Director of Major Trauma & Neuro Intensive Care Consultant at Southampton University Hospital in Southampton, UK, and BiO2 Medical's Chief Medical Officer, Dr. Luis Angel, inventor of the Angel' Catheter and Associate Professor of Pulmonary and Critical Care Medicine at the University of Texas Health Science Center in San Antonio, Texas.

According to Christopher E. Banas, BiO2 Medical's Chairman and Chief Executive Officer, "This represents an important milestone for BiO2 Medical and the commercialization of the Angel' Catheter. We are pleased to provide physicians with a technology that offers immediate Pulmonary Embolism protection for ICU patients during the critical unprotected window, while simultaneously allowing for lifesaving fluid and medication administration."

BiO2 Medical is a medical device manufacturer founded to design, develop, and subsequently manufacture a range of medical products in response to clinical needs. For more information regarding BiO2 Medical and the Angel' Catheter, please visit www.bio2medical.com.

SOURCE BiO2 Medical, Inc.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.